Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Frigault

Showing results (51-60 of 117) with videos related to

Pageof 12
Sort By:
Transplantation and Cellular Therapy|November 9, 2025
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy StudiesFrederick L Locke, Sarah Nikiforow, Matthew J Frigault, et al.
Bone Marrow Transplantation|May 28, 2020
Ciprofloxacin prophylaxis is associated with a lower incidence of gram-negative bacteremia in patients undergoing allogeneic hematopoietic cell transplantationA Katie Maurer, Shuli Li, Bradley D Hunter, et al.
Blood|August 10, 2018
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomasIrene Scarfò, Maria Ormhøj, Matthew J Frigault, et al.
Blood|July 20, 2019
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphomaMatthew J Frigault, Jorg Dietrich, Maria Martinez-Lage, et al.
Blood|March 16, 2025
Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 StudyMatthew J Frigault, Richard T Maziarz, Jae H Park, et al.
The Journal of Allergy and Clinical Immunology|November 6, 2024
Association of CD19<sup>+</sup>-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortalityNatalia M Sutherland, Baijun Zhou, Lingxiao Zhang, et al.
International Journal of Radiation Oncology, Biology, Physics|April 3, 2025
5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell LymphomaHazim S Ababneh, Andrea K Ng, Joshua Wan, et al.
Journal for Immunotherapy of Cancer|January 8, 2022
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)Marc Wehrli, Kathleen Gallagher, Yi-Bin Chen, et al.
Cancer Cell|April 22, 2022
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemiaMark B Leick, Harrison Silva, Irene Scarfò, et al.
Blood Advances|January 7, 2020
Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangementValentina Nardi, Nora Ku, Matthew J Frigault, et al.
Pageof 12

Showing results (51-60 of 117) with videos related to

Sort By:
Pageof 12
Transplantation and Cellular Therapy|November 9, 2025
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy StudiesFrederick L Locke, Sarah Nikiforow, Matthew J Frigault, et al.
Bone Marrow Transplantation|May 28, 2020
Ciprofloxacin prophylaxis is associated with a lower incidence of gram-negative bacteremia in patients undergoing allogeneic hematopoietic cell transplantationA Katie Maurer, Shuli Li, Bradley D Hunter, et al.
Blood|August 10, 2018
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomasIrene Scarfò, Maria Ormhøj, Matthew J Frigault, et al.
Blood|July 20, 2019
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphomaMatthew J Frigault, Jorg Dietrich, Maria Martinez-Lage, et al.
Blood|March 16, 2025
Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 StudyMatthew J Frigault, Richard T Maziarz, Jae H Park, et al.
The Journal of Allergy and Clinical Immunology|November 6, 2024
Association of CD19<sup>+</sup>-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortalityNatalia M Sutherland, Baijun Zhou, Lingxiao Zhang, et al.
International Journal of Radiation Oncology, Biology, Physics|April 3, 2025
5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell LymphomaHazim S Ababneh, Andrea K Ng, Joshua Wan, et al.
Journal for Immunotherapy of Cancer|January 8, 2022
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)Marc Wehrli, Kathleen Gallagher, Yi-Bin Chen, et al.
Cancer Cell|April 22, 2022
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemiaMark B Leick, Harrison Silva, Irene Scarfò, et al.
Blood Advances|January 7, 2020
Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangementValentina Nardi, Nora Ku, Matthew J Frigault, et al.
Pageof 12